argenx SE Share Price

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 09:07:46 21/06/2024 pm IST 5-day change 1st Jan Change
371.8 EUR +3.65% Intraday chart for argenx SE +3.02% +8.24%

Financials

Sales 2024 * 1.71B 1.83B 153B Sales 2025 * 2.29B 2.45B 205B Capitalization 22.1B 23.62B 1,974B
Net income 2024 * -147M -157M -13.13B Net income 2025 * 171M 183M 15.28B EV / Sales 2024 * 11.5 x
Net cash position 2024 * 2.36B 2.53B 211B Net cash position 2025 * 2.55B 2.73B 228B EV / Sales 2025 * 8.53 x
P/E ratio 2024 *
-154 x
P/E ratio 2025 *
128 x
Employees 1,148
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
Argenx Gets FDA Approval for Chronic Inflammatory Demyelinating Polyneuropathy Treatment DJ
Wedbush Adjusts Price Target on argenx to $519 From $521, Maintains Outperform Rating MT
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee CI
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading MT
Transcript : Argenx SE Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading MT
Transcript : Argenx SE Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
JPMorgan Cuts Price Target on Argenx to $500 From $560, Maintains Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
Indexes already back on top Our Logo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Fading Rate Cut Hopes MT
More news
1 day+3.65%
1 week+3.02%
Current month+9.13%
1 month+12.73%
3 months-0.03%
6 months+24.47%
Current year+8.24%
More quotes
1 week
348.20
Extreme 348.2
371.80
1 month
330.30
Extreme 330.3
371.80
Current year
322.50
Extreme 322.5
381.10
1 year
271.00
Extreme 271
494.10
3 years
224.10
Extreme 224.1
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 01/08/01
Director of Finance/CFO 54 01/21/01
Chief Tech/Sci/R&D Officer - 01/15/01
Members of the board TitleAgeSince
Director/Board Member 71 26/17/26
Director/Board Member 74 13/15/13
Director/Board Member 63 28/16/28
More insiders
Date Price Change Volume
21/24/21 371.8 +3.65% 286,132
20/24/20 358.7 +1.44% 53,032
19/24/19 353.6 -0.65% 21,034
18/24/18 355.9 +0.08% 49,281
17/24/17 355.6 -1.47% 42,679

Real-time Euronext Bruxelles, June 21, 2024 at 09:07 pm IST

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
16/07/2024 - R&D Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
371.8 EUR
Average target price
439.5 EUR
Spread / Average Target
+18.22%
Consensus